Cannabis News

Curaleaf's Select Brand Expands into Utah

America's #1 Cannabis Oil Brand is now available in 17 States

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading U.S. provider of consumer products in cannabis, today announced that it would expand its line of Select brand products into Utah starting with the brand's popular Select Elite cartridges.

Select, America's #1 Cannabis Oil Brand, was acquired by Curaleaf in February 2020 , and is currently available across 17 states including Arizona , California , Colorado , Connecticut , Florida , Illinois , Maine , Massachusetts , Michigan , Maryland , New York , Nevada , Ohio , Oklahoma , Oregon , Pennsylvania , and Utah .

Select Elite will be accessible to patients at medical cannabis pharmacies across the state in the coming weeks, starting with immediate availability at the Curaleaf pharmacy in Lehi, UT . As one of the fourteen licensed retailers to operate within Utah's medical market, Curaleaf Lehi has proudly served thousands of Utah's 18,400+ active patient cardholders and looks forward to providing more accessibility to high-quality medical cannabis products, innovative consumption formats, and leading national brands to the state's growing patient base.

Select Elite cartridges deliver an activated, broad-spectrum oil and a smooth vaping experience made possible by the brand's proprietary distillation process. As an industry leader in the vape market, Select sets superior quality control and testing standards while delivering consistent, premium experiences. Curaleaf looks forward to introducing more offerings from Select's diverse product line in the coming months that will cater to more medicinal needs.

"Select has been part of Curaleaf's family of brands since early 2020; our team has seen firsthand how well-received the brand has been in every market we've entered, and we are delighted to introduce Select Elite to Utah's medical cannabis community," said Joe Bayern , CEO of Curaleaf. "Our passion for serving our patients is reflected not only in our commitment to providing high-quality products but also in our mission to educate our patients so they make empowered choices throughout their cannabis journeys."

During the COVID-19 outbreak, cannabis businesses have been deemed an essential service in most states, including Utah . Curaleaf remains committed to serving patients with the products and service they rely on while implementing heightened safety and sanitation measures in all its facilities. To find a Pharmacy near you that carries Select products, go to https://shop-lehiut.curaleaf.com/ and click "Find Us" for an interactive map of locations.

About Curaleaf Holdings, Inc.
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf") is the leading vertically integrated U.S. multi-state cannabis operator with a mission to improve lives by providing clarity around cannabis and confidence around consumption. As a high-growth cannabis company known for quality, expertise and reliability, the Company and its brands, including Curaleaf and Select, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. Curaleaf currently operates in 23 states with 101 dispensaries, 22 cultivation sites and over 30 processing sites, and employs over 3,000 team members across the United States . Curaleaf is listed on the Canadian Securities Exchange under the symbol CURA and trades on the OTCQX market under the symbol CURLF. For more information, please visit www.curaleaf.com .

INVESTOR CONTACT
Curaleaf Holdings, Inc.
Investor Relations
IR@curaleaf.com

MEDIA CONTACT
Curaleaf Holdings, Inc.
Tracy Brady , VP Corporate Communications
media@curaleaf.com

FORWARD-LOOKING STATEMENTS
This media advisory contains forward–looking statements and forward–looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", "expects" or, "proposed", "is expected", "intends", "anticipates", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. More particularly and without limitation, this news release contains forward-looking statements and information concerning the expansion of the Select brand and its product offerings in Utah . Such forward-looking statements and information reflect management's current beliefs and are based on assumptions made by and information currently available to the Company with respect to the matter described in this new release. Forward-looking statements involve risks and uncertainties, which are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information about these assumptions and risks and uncertainties is contained under "Risk Factors and Uncertainties" in the Company's latest annual information form filed September 23, 2019 , which is available under the Company's SEDAR profile at www.sedar.com , and in other filings that the Company has made and may make with applicable securities authorities in the future. Forward-looking statements contained herein are made only as to the date of this press release and we undertake no obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.

Cision View original content: http://www.prnewswire.com/news-releases/curaleafs-select-brand-expands-into-utah-301232317.html

SOURCE Curaleaf Holdings, Inc.

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
stock chart

Cannabis Weekly Round-Up: Fresh Quarterly Results Highlight Market Struggles

The cannabis industry's struggles were showcased this past week as several companies released financial results.

Operators across the US and Canada face various challenges when trying to grow and sell cannabis, and their financial results offer investors a closer look at the challenges these companies are facing.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading...Show less

HEY MARYLAND, ORANGE YA GLAD GAGE CANNABIS HAS ARRIVED?

TerrAscend Corp. ("TerrAscend" or the "Company") (CSE: TER) (OTCQX: TRSSF), a leading North American cannabis operator, today announced that its Gage Cannabis Co. branded products are now available in Maryland . Known for its world-class genetics, high-quality flower and its iconic Orange logo, Gage cultivates cannabis with uncompromising standards for customers who love and respect the plant. The initial "Free State" product launch features highly sought-after and exclusive flower strains, including Banana Bread, Dream Candy, Grape Gummiez, Sundae Driver and Popscotti.

TerrAscend Corp. Logo (CNW Group/TerrAscend)

TerrAscend plans to offer more Gage products including accessories, apparel and more of its unique strains of flower, pre-rolls, vape cartridges and concentrates as the state progresses towards its expected adult-use launch this summer.

"Gage has earned its popularity and exceptional reputation," said Jason Wild , Executive Chairman of TerrAscend. "We are proud to bring this brand to cannabis enthusiasts in Maryland . Cannabis consumers expectations are rising and we are excited to expand our offering of high quality Gage products in this important state."

Gage plans to expand quickly into more fan-favorite cannabis categories: to find up-to-date information on local products, follow @gagemaryland on Instagram.

About TerrAscend

TerrAscend is a leading North American cannabis operator with vertically integrated operations in Pennsylvania , New Jersey , Maryland , Michigan and California and licensed production in Canada . TerrAscend operates The Apothecarium and Gage dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. TerrAscend's cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use markets. The Company owns several synergistic businesses and brands including Gage Cannabis, The Apothecarium, Ilera Healthcare, Kind Tree, Legend, State Flower, Valhalla Confections, and Arise Bioscience Inc. For more information visit www.terrascend.com .

About Gage

Gage is a premier provider of the high-quality cannabis experience that consumers crave and deserve. Known for world-class genetics, Gage cultivates exceptional cannabis with uncompromising high standards for customers who love and respect the potency of flower. We are passionate about innovating and curating the best premium cannabis products. Gage debuted in Michigan in 2019 and has expanded to Pennsylvania , New Jersey , and Maryland . To learn more about Gage's mission for the everyday canna-connoisseur, visit www.gagecannabis.com .

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States . Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to, among other things, cultivate, distribute or possess cannabis in the United States . Financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under U.S. federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend. The enforcement of federal laws in the United States is a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend's operations and financial performance.

Forward Looking Information

This news release contains "forward-looking information" within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, "may", "would", "could", "will", "likely", "expect", "anticipate", "believe, "intend", "plan", "forecast", "project", "estimate", "outlook" and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management's experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits.

Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, current and future market conditions; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States ; and the risk factors set out in the Company's most recently filed MD&A, filed with the Canadian securities regulators and available under the Company's profile on SEDAR at www.sedar.com and in the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission on March 17, 2022 and as amended on March 24, 2022 .

The statements in this press release are made as of the date of this release. TerrAscend disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE TerrAscend

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2023/09/c7765.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Curaleaf and Fab 5 Freddy Launch B Noble Cannabis Brand in Florida

B NOBLE brings a high-quality, Black-owned cannabis brand to Curaleaf's 58 retail locations in the Sunshine State

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer cannabis products, today announced the expansion of its B NOBLE partnership across Florida . Products from the high-quality, Black-owned cannabis brand will be available at Curaleaf's 58 dispensaries across the state.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve Opening Medical Marijuana Dispensary in Palatka, FL

New dispensary expands patient access to medical cannabis; grand opening specials available

9 p.m. from Monday through Saturday and 10 a.m8 p.m. on Sunday .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Cresco Labs Continues Florida Expansion with Two New Store Openings

Photo caption: Cresco Labs opened new stores in Palm Harbor and Lake Worth, bringing the company's Florida footprint to 28 dispensaries.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) ("Cresco" or "the Company), a vertically integrated multistate cannabis operator and the No. 1 U.S. wholesaler of branded products, today announced its Florida retail footprint has grown to 28 total dispensaries with today's store openings in Palm Harbor and Lake Worth. The Company's continued expansion brings its nationwide store count to 63.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Trulieve Reports Fourth Quarter and Record Full Year 2022 Results Exceeding $1.2 Billion in Revenue

  • Record revenue of $1.24 billion in 2022, up 32% year over year, and quarterly revenue of $302 million , with 2% retail revenue growth sequentially
  • Industry leading U.S. retail network of 181 dispensaries, up 14% from 2021, supported by over 4 million square feet of cultivation and processing capacity as of December 31, 2022
  • Achieved fourth quarter operating cash flow of $55 million and free cash flow of $21 million

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced its results for the fourth quarter and full year ended December 31, 2022 . Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles unless otherwise indicated. Numbers may not sum perfectly due to rounding.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Q4 2022 Financial and Operational Highlights*

  • Revenue of $302 million , with 2% retail revenue growth and 96% of revenue from retail sales.
  • Achieved GAAP gross margin of 50%, with gross profit of $150 million .
  • Reported net loss of $77 million . Adjusted net loss of $35 million * excludes non-recurring charges, asset impairments, disposals and discontinued operations.
  • Generated adjusted EBITDA of $85 million *, or 28% of revenue. Adjusted EBITDA reflects one time charges, idle capacity, and inventory reduction tied to cash generation efforts.
  • Reduced inventory by $4 million versus $32 million build in the third quarter.
  • Achieved operating cash flow of $55 million and free cash flow of $21 million .
  • Closed $90 million in commercial loans with average interest rate of 7.5% interest.
  • Opened five new dispensaries in Sierra Vista, Arizona ; Hobe Sound , Lake Worth , and Land O' Lakes, Florida ; and Huntington, West Virginia and rebranded Trulieve dispensary in Glendale, Arizona .

*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

2022 Full Year Financial and Operational Highlights*

  • Revenue of $1.2 billion increased 32% year-over-year.
  • Gross profit of $682 million and gross margin of 55% in 2022.
  • GAAP net loss of $246 million and adjusted net loss of $30 million *, which excludes non-recurring charges, asset impairments, disposals and discontinued operations, associated with the Harvest acquisition and strategic repositioning of assets to improve cash flow.
  • Adjusted EBITDA of $400 million , or 32% of revenue.*
  • Cash at year end of $219 million .
  • Closed $75 million in senior secured notes at 8% interest due October 2026 .
  • Commenced cultivation operations in Georgia to support retail launch in 2023.
  • Opened 25 dispensaries in 2022, increasing retail footprint by 14% to 181 retail locations nationwide at year end.
  • Exited 2022 with operations in 11 states, with 32% of our retail locations outside of the state of Florida

*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

Recent Developments

  • Opened three new dispensaries in Palatka and Winter Haven, Florida and Beckley, West Virginia .
  • Launched adult-use sales in Bristol, Connecticut .
  • First U.S. cannabis company to launch advertising campaigns on Twitter.
  • Launched proprietary brands Roll One and Modern Flower in West Virginia and Massachusetts .
  • Currently operate 184 retail dispensaries and over 4 million square feet of cultivation and processing capacity in the United States .

Management Commentary

"Trulieve has grown to surpass $1.2 billion in revenue in less than seven years, a notable milestone and a testament to the agility of our team," said Kim Rivers , Trulieve CEO. "Our success is the culmination of thoughtful intention, superb execution, and best in class capabilities for rapid growth."

Rivers continued, "With increasing mainstream support and meaningful regulatory reform on the horizon, tremendous growth opportunities lie ahead for U.S. legal cannabis. In 2023, we are laser focused on cash generation while investing to build a sustainable company designed to thrive in an integrated commerce environment."

Financial Highlights*

Results of Operations

For the Three Months Ended

For the Full Year Ended



(Figures in millions and % change
based on these figures)

December
31, 2022

December
31, 2021

change

September
30, 2022

change

December
31, 2022

December
31, 2021

change



Revenue

$

302

$

305

-1 %

$

301

0 %

$

1,240

$

938

32 %


Gross Profit

$

150

$

134

12 %

$

168

-11 %

$

682

$

568

20 %


Gross Margin %


50 %


44 %



56 %



55 %


61 %



Adjusted Gross Profit

$

162

$

181

-10 %

$

172

-6 %

$

703

$

621

13 %


Adjusted Gross Margin %


54 %


59 %



57 %



57 %


66 %



Operating Expenses

$

156

$

150

4 %

$

198

-21 %

$

650

$

368

77 %


Operating Expenses %


52 %


49 %



65 %



52 %


39 %



Net Income (Loss)**

$

(77)

$

(72)

---

$

(115)

---

$

(246)

$

18

---


Net Income (Loss) Continuing Ops

$

(76)

$

(70)

---

$

(77)

---

$

(205)

$

19

---


Adjusted Net Income (Loss)

$

(35)

$

2

---

$

4

---

$

(30)

$

123

---


Diluted Shares Outstanding


189


145



189



188


147



EPS Continuing Ops

$

(0.40)

$

(0.48)

---

$

(0.41)

---

$

(1.06)

$

0.14

---


Adjusted EPS

$

(0.18)

$

0.01

---

$

0.02

---

$

(0.16)

$

0.84

---


Adjusted EBITDA

$

85

$

101

-16 %

$

99

-14 %

$

400

$

385

4 %


Adjusted EBITDA Margin %


28 %


33 %



33 %



32 %


41 %




*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

**Includes discontinued operations.

Conference Call

The Company will host a conference call and live audio webcast on March 8 , 2023, at 8:30 A.M. Eastern time , to discuss its fourth quarter and full year 2022 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.

North American toll free: 1-888-317-6003

Passcode: 0344386

International: 1-412-317-6061

Passcode: 0344386

A live audio webcast of the conference call will be available at:
https://app.webinar.net/ablVoLE61N3

A powerpoint presentation and archived replay of the webcast will be available at:
https://investors.trulieve.com/events

The Company's Form 10-K for the year ended December 31, 2022 , will be available on the SEC's website or at https://investors.trulieve.com/annual-reports-and-proxy . The Company's Management Discussion and Analysis for the period and the accompanying financial statements and notes will be available under the Company's profile on SEDAR and on its website at https://investors.trulieve.com/quarterly-results . This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.

Trulieve Cannabis Corp.
Consolidated Balance Sheets
(in millions)




2022



2021

ASSETS






Current Assets:






Cash and cash equivalents


$

212.3



$

230.1

Restricted cash



6.6




3.0

Accounts receivable, net



9.4




8.6

Inventories, net



297.8




209.9

Prepaid expenses and other current assets



63.6




68.1

Notes receivable - current portion



0.7




1.5

Assets associated with discontinued operations



2.5




3.6

Total current assets



593.0




524.9

Property and equipment, net



796.9




779.4

Right of use assets - operating, net



101.4




111.7

Right of use assets - finance, net



76.2




66.8

Intangible assets, net



1,012.6




1,081.2

Goodwill



791.5




765.4

Notes receivable, net



12.0




12.1

Other assets



14.7




17.6

Long-term assets associated with discontinued operations



0.7




52.2

TOTAL ASSETS


$

3,399.0



$

3,411.4

LIABILITIES






Current Liabilities:






Accounts payable and accrued liabilities


$

83.2



$

93.8

Income tax payable



49.0




28.1

Deferred revenue



9.5




7.2

Notes payable - current portion, net



12.5




10.1

Operating lease liabilities - current portion



10.4




10.0

Finance lease liabilities - current portion



8.7




6.2

Construction finance liabilities - current portion



1.2




0.9

Contingencies



34.7




13.0

Liabilities associated with discontinued operations



0.5




0.1

Total current liabilities



209.7




169.4

Long-Term Liabilities:






Notes payable, net



94.2




6.5

Private placement notes, net



541.7




462.9

Warrant liabilities



0.3




2.9

Operating lease liabilities



102.4




107.6

Finance lease liabilities



75.8




65.2

Construction finance liabilities



182.4




175.2

Deferred tax liabilities



224.1




241.9

Other long-term liabilities



26.2




8.4

Long-term liabilities associated with discontinued operations



14.6




24.0

TOTAL LIABILITIES



1,471.3




1,264.0

Commitments and contingencies






SHAREHOLDERS' EQUITY






Common Stock, no par value; unlimited shares authorized. 185,987,512 and 180,504,172 issued and outstanding as of December 31, 2022 and December 31, 2021, respectively.






Additional paid-in-capital



2,045.0




2,008.1

Accumulated (deficit) earnings



(113.8)




137.7

Non-controlling interest



(3.5)




1.6

TOTAL SHAREHOLDERS' EQUITY



1,927.7




2,147.4

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY


$

3,399.0



$

3,411.4

Trulieve Cannabis Corp.
Consolidated Statements of Operations and Comprehensive (Loss) Income
(in millions, except per share data)




Three Months Ended



Full Year Ended




December 31,
2022



December 31,
2021



December 31,
2022



December 31,
2021


Revenues, net of discounts


$

302.2



$

304.9



$

1,239.8



$

938.0


Cost of goods sold



152.5




170.8




557.8




370.2


Gross profit



149.7




134.1




682.0




567.8


Expenses:













Sales and marketing



60.9




72.3




284.9




215.1


General and administrative



64.9




44.6




169.7




100.5


Depreciation and amortization



30.7




27.4




119.4




47.2


Impairment and disposal of long-lived assets, net



(0.6)




5.4




75.5




5.4


Total expenses



155.9




149.7




649.6




368.3


(Loss) Income from operations



(6.3)




(15.6)




32.4




199.6


Other income (expense):













Interest expense



(23.0)




(14.1)




(79.8)




(34.8)


Change in fair value of derivative liabilities - warrants



0.0




0.2




2.6




0.2


Other income (expense), net



(1.6)




0.7




1.4




1.1


Total other expense, net



(24.6)




(13.2)




(75.8)




(33.5)


(Loss) Income before provision for income taxes



(30.8)




(28.7)




(43.3)




166.1


Provision for income taxes



45.1




41.4




161.8




146.7


Net (loss) income from continuing operations and comprehensive (loss) income



(75.9)




(70.2)




(205.2)




19.4


Net loss from discontinued operations, net of tax benefit of ($3,776), $642, $10,663, and $642, respectively



(5.2)




(1.9)




(47.6)




(1.9)


Net (loss) income



(81.2)




(72.1)




(252.7)




17.4


Less: Net loss and comprehensive loss attributable to non-controlling interest from continuing operations



(4.1)




(0.6)




(6.7)




(0.6)


Net (loss) income and comprehensive (loss) income attributable to common shareholders


$

(77.0)



$

(71.5)



$

(246.1)



$

18.0















Net (loss) income per share - Continuing operations:













Basic and diluted


$

(0.40)



$

(0.48)



$

(1.06)



$

0.14


Net loss per share - Discontinued operations:













Basic and diluted


$

(0.03)



$

(0.01)



$

(0.25)



$

(0.01)


Weighted average number of common shares used in computing net (loss) income per share:













Basic



188.8




145.1




188.0




139.4


Diluted



188.8




145.1




188.0




146.8


Non-GAAP Financial Measures
In addition to our results determined in accordance with GAAP, we supplement our results with non-GAAP financial measures, including adjusted EBITDA, adjusted gross profit, adjusted net income (loss), adjusted net income (loss) per diluted share. Our management uses these non-GAAP financial measures in conjunction with GAAP financial measures to evaluate our operating results and financial performance. We believe these measures are useful to investors as they are widely used measures of performance and can facilitate comparison to other companies. These non-GAAP financial measures are not, and should not be considered as, measures of liquidity. These non-GAAP financial measures have limitations as analytical tools in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Because of these limitations, these non-GAAP financial measures should be considered along with GAAP financial performance measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures can be found below. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP.

Reconciliation of Non-GAAP Adjusted EBITDA
The following table presents a reconciliation of GAAP net income (loss) to non-GAAP Adjusted EBITDA, for each of the periods presented:

(Amounts expressed in millions of United States
dollars)

For the Three Months Ended

For the Full Year Ended





December
31, 2022

December
31, 2021

September
30, 2022

December
31, 2022

December
31, 2021





Net Income (Loss) GAAP

$

(77.0)

$

(71.5)

$

(114.6)

$

(246.1)

$

18.0



Add (Deduct) Impact of:













Interest Expense, net

$

23.0

$

14.1

$

19.3

$

79.8

$

34.8



Provision For Income Taxes

$

45.1

$

41.4

$

28.2

$

161.8

$

146.7



Depreciation and Amortization

$

30.7

$

27.4

$

30.2

$

119.4

$

47.2



Depreciation in COGS

$

13.4

$

9.7

$

14.6

$

52.5

$

24.1



EBITDA

$

35.2

$

21.1

$

(22.3)

$

167.4

$

270.8
















Impairment and Disposal of Long-lived Assets, net

$

(0.6)

$

5.4

$

54.6

$

75.5

$

5.4



Results of Discontinued Operations

$

5.2

$

1.9

$

38.1

$

47.6

$

1.9



Acquisition and Transaction Costs

$

7.5

$

1.5

$

7.0

$

24.8

$

15.8



Integration and Transition Costs

$

4.0

$

22.9

$

6.7

$

21.1

$

25.6



Other Non-Recurring Costs

$

16.3

$

3.4

$

1.9

$

27.8

$

5.1



Share-Based Compensation and Related Premiums

$

3.6

$

7.0

$

4.3

$

18.1

$

13.4



Legislative Campaign Contributions

$

10.0

$

0.0

$

10.0

$

20.0

$

0.0



Inventory Step Up Fair Value

$

0.0

$

38.0

$

0.0

$

1.0

$

41.2



Covid Related Expenses

$

0.0

$

0.2

$

0.2

$

0.8

$

6.2



Other Expense (Income), net

$

1.6

$

(0.7)

$

(0.4)

$

(1.4)

$

(1.1)



Fair Value of Derivative Liabilities - Warrants

$

(0.0)

$

(0.2)

$

(0.4)

$

(2.6)

$

(0.2)



Results of Entities Not Legally Controlled

$

1.9

$

0.5

$

(0.9)

$

(0.0)

$

0.5



Adjusted EBITDA Non-GAAP

$

84.7

$

100.9

$

98.8

$

400.1

$

384.6



Reconciliation of Non-GAAP Adjusted Gross Profit
The following table presents a reconciliation of GAAP gross profit to non-GAAP adjusted gross profit, for each of the periods presented:

(Amounts expressed in millions of United States
dollars)

For the Three Months Ended

For the Full Year Ended





December
31, 2022

December
31, 2021

September
30, 2022

December
31, 2022

December
31, 2021





Gross Profit GAAP

$

149.7

$

134.1

$

168.0

$

682.0

$

567.8



Gross Margin % GAAP


50 %


44 %


56 %


55 %


61 %



Add (Deduct) Impact of:



Inventory Step Up Fair Value

$

0.0

$

38.0

$

0.0

$

1.0

$

41.2



Transaction, Acquisition, and Integration Costs

$

12.4

$

8.5

$

3.8

$

19.8

$

12.4



Adjusted Gross Profit Non-GAAP

$

162.1

$

180.6

$

171.9

$

702.9

$

621.4



Adjusted Gross Margin % Non-GAAP


54 %


59 %


57 %


57 %


66 %



Reconciliation of Non-GAAP Adjusted Net Income
The following table presents a reconciliation of GAAP net income (loss) to non-GAAP adjusted net income, for each of the periods presented:

(Amounts expressed in millions of United States
dollars)

For the Three Months Ended

For the Full Year Ended





December

31, 2022

December
31, 2021

September
30, 2022

December
31, 2022

December
31, 2021





Net Income (Loss) GAAP

$

(77.0)

$

(71.5)

$

(114.6)

$

(246.1)

$

18.0



Add (Deduct) Impact of:













Share-Based Compensation Related Premiums

$

0.0

$

0.0

$

0.0

$

0.0

$

4.2



Fair Value of Derivative Liabilities - Warrants

$

(0.0)

$

(0.2)

$

(0.4)

$

(2.6)

$

(0.2)



Inventory Step Up Fair Value

$

0.0

$

38.0

$

0.0

$

1.0

$

41.2



Transaction, Acquisition, and Integration Costs

$

37.8

$

27.9

$

25.5

$

93.7

$

46.5



Covid Related Expenses

$

0.0

$

0.2

$

0.2

$

0.8

$

6.2



Impairment and Disposal of Long-lived Assets, Net

$

(0.6)

$

5.4

$

54.6

$

75.5

$

5.4



Results of Discontinued Operations


5.2

$

1.9

$

38.1

$

47.6

$

1.9



Adjusted Net Income (Loss) Non-GAAP

$

(34.7)

$

1.5

$

3.5

$

(30.1)

$

123.2



Reconciliation of Non-GAAP Adjusted Earnings Per Share
The following table presents a reconciliation of GAAP earnings (loss) per share to non-GAAP adjusted earnings per share, for each of the periods presented:

(Amounts expressed in millions of United States
dollars)

For the Three Months Ended

For the Full Year Ended





December
31, 2022

December
31, 2021

September
30, 2022

December
31, 2022

December
31, 2021





Earnings (Loss) Per Share GAAP

$

(0.41)

$

(0.49)

$

(0.61)

$

(1.31)

$

0.12



Add (Deduct) Impact of:













Share-Based Compensation Related Premiums

$

0.00

$

0.00

$

0.00

$

0.00

$

0.03



Fair Value of Derivative Liabilities - Warrants

$

(0.00)

$

(0.00)

$

(0.00)

$

(0.01)

$

(0.00)



Inventory Step Up Fair Value

$

0.00

$

0.26

$

0.00

$

0.01

$

0.28



Transaction, Acquisition, and Integration Costs

$

0.20

$

0.19

$

0.14

$

0.50

$

0.32



Covid Related Expenses

$

0.00

$

0.00

$

0.00

$

0.00

$

0.04



Impairment and Disposal of Long-lived Assets, Net

$

(0.00)

$

0.04

$

0.29

$

0.40

$

0.04



Results of Discontinued Operations

$

0.03

$

0.01

$

0.20

$

0.25

$

0.01



Adjusted Earnings Per Share Non-GAAP

$

(0.18)

$

0.01

$

0.02

$

(0.16)

$

0.84



Forward-Looking Statements
This news release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to the Company's expectations or forecasts of business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs and include statements regarding cannabis regulatory reform, the Company's growth opportunities and the Company's investment plans for sustainable growth. Words such as "expects", "continue", "will", "anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company's current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risks discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and in our periodic reports subsequently filed with the United Sates Securities and Exchange Commission and in the Company's filings on SEDAR at www.sedar.com . Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve _
Twitter: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Rob Kremer , Executive Director of Corporate Communications
+1 (404) 218-3077
Robert.Kremer@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-reports-fourth-quarter-and-record-full-year-2022-results-exceeding-1-2-billion-in-revenue-301765204.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/March2023/08/c4481.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×